Cyclomydril
Generic: CYCLOPENTOLATE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE
Basic Information
Manufacturer
Alcon Laboratories, Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
OPHTHALMIC
FDA Set ID
8268b70f-3f10-48dd-bb24-baaeb27a1325
Indications & Usage
INDICATIONS AND USAGE For the production of mydriasis.
Warnings
WARNINGS FOR TOPICAL OPHTHALMIC USE ONLY.
NOT FOR INJECTION.
There have been reports of serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, in patients using higher concentrations of phenylephrine.
These episodes, some fatal, have usually occurred in patients with pre-existing cardiovascular diseases.
This preparation may cause central nervous system (CNS) disturbances.
This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions.
Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate.
NOT FOR INJECTION.
There have been reports of serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, in patients using higher concentrations of phenylephrine.
These episodes, some fatal, have usually occurred in patients with pre-existing cardiovascular diseases.
This preparation may cause central nervous system (CNS) disturbances.
This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions.
Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate.
Adverse Reactions
ADVERSE REACTIONS Ocular The following ocular adverse experiences have been associated with the use of CYCLOMYDRIL ® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution): increased intraocular pressure, burning/irritation upon instillation, photophobia, blurred vision and superficial punctate keratitis.
Nonocular Use of cyclopentolate hydrochloride has been associated with psychotic reactions and behavioral disturbances in children.
These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place.
This drug produces reactions similar to those of other adrenergic and anticholinergic drugs; however, the central nervous system manifestations as noted above are most common.
Other manifestations of adrenergic and anticholinergic topical ophthalmic drugs include tachycardia, hyperpyrexia, hypertension, vasodilation, urinary retention, diminished gastrointestinal motility, convulsion, bradycardia, apnea, necrotizing colitis and abdominal distention (in newborns and especially premature infants), skin rash, drowsiness, and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages.
Severe manifestations of toxicity include coma, medullary paralysis and death.
Systemic toxicity can result from topical application of sympathomimetic drugs: headache, blood pressure elevation, extrasystoles, tachycardia, syncope and cerebrovascular accidents have been reported.
Nonocular Use of cyclopentolate hydrochloride has been associated with psychotic reactions and behavioral disturbances in children.
These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place.
This drug produces reactions similar to those of other adrenergic and anticholinergic drugs; however, the central nervous system manifestations as noted above are most common.
Other manifestations of adrenergic and anticholinergic topical ophthalmic drugs include tachycardia, hyperpyrexia, hypertension, vasodilation, urinary retention, diminished gastrointestinal motility, convulsion, bradycardia, apnea, necrotizing colitis and abdominal distention (in newborns and especially premature infants), skin rash, drowsiness, and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages.
Severe manifestations of toxicity include coma, medullary paralysis and death.
Systemic toxicity can result from topical application of sympathomimetic drugs: headache, blood pressure elevation, extrasystoles, tachycardia, syncope and cerebrovascular accidents have been reported.